Breast Cancer Clinical Trials

NRG-BR003

A randomized Phase III trial of adjuvant therapy comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative triple-negative invasive breast cancer. Click here to learn more.

HERMIONE

MM-302 plus Trastuzumab vs. chemotherapy of physician’s choice plus Trastuzumab in HER2-positive locally advanced/metastatic breast cancer patients. Click here to learn more.

S1207

Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-positive and HER2/Neu negative breast cancer

NLG2101

A Phase 2 double-blinded, randomized, placebo-controlled study of Indoximod in combination with a taxane chemotherapy in metastatic breast cancer.

EMBRACA  

A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) Versus Physician’s Choice in Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic Disease. Click here to learn more.

EMR200647-001

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications. Click here to learn more.

UCBC